Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models
Combination therapy with ribociclib and trametinib significantly prolonged survival in the GEM model but not in the PDX model, highlighting the importance of testing novel therapies in diverse models.
Authors
- Gonzalo Piñero (ORCID: https://orcid.org/0000-0001-8510-9598)
- Eita Uchida (ORCID: https://orcid.org/0000-0002-3056-5446)
- Tammy Hennika (ORCID: https://orcid.org/0000-0001-9264-6498)
- Dolores Hambardzumyan
- Gabrielle Link
- Anna Racanelli
- Ivan Spasojević (ORCID: https://orcid.org/0000-0001-9890-6246)
- Megan M. Romero
- Samantha Gadd
- Rintaro Hashizume
- Oren J. Becher
- Emma R. H. Gold
- Yi Ge
- Daniel J. Brat
- Herminio Joey Cardona
- Yusuke Tomita
- Jun Watanabe
- Nozomu Takata
- Guo Hu
- Adam L. Green
Institutions
- Northwestern University (US)
- Lurie Children's Hospital (US)
- Mount Sinai Health System (US)
- Duke University (US)
- Baylor College of Medicine (US)
- Children's of Alabama (US)
- University of Alabama at Birmingham (US)
- Morgan Adams Foundation (US)
- Mount Sinai Hospital (US)
- Hiroshima City Asa Citizens Hospital (JP)
- Lurie Children's Hospital (US)
- Duke Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1371/journal.pone.0323235
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00